6966-87-6

Basic information

• Product Name: (2E)-2-(HYDROXYIMINO)-N-(3-METHOXYPHENYL)ACETAMIDE
• Synonyms: m-Glyoxylanisidide,2-oxime (8CI); m-Glyoxylanisidide, oxime (6CI);2-Hydroxyimino-N-(3-methoxyphenyl)acetamide; NSC 68224
• CAS NO: 6966-87-6
• Molecular Formula: C₉H₁₀N₂O₃
• Molecular Weight: 194.1873
• Mol File: 6966-87-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.22g/cm³
• Refractive Index: 1.549
• CAS DataBase Reference: (2E)-2-(HYDROXYIMINO)-N-(3-METHOXYPHENYL)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (2E)-2-(HYDROXYIMINO)-N-(3-METHOXYPHENYL)ACETAMIDE(6966-87-6)
• EPA Substance Registry System: (2E)-2-(HYDROXYIMINO)-N-(3-METHOXYPHENYL)ACETAMIDE(6966-87-6)

Safety Data

• Hazardous Substances Data: 6966-87-6(Hazardous Substances Data)

Usage

Description

(2E)-2-(Hydroxyimino)-N-(3-methoxyphenyl)acetamide is a chemical compound derived from acetamide, featuring a hydroxyimino group at the 2 position and a 3-methoxyphenyl group at the N position. Its unique structure suggests potential interactions with biological targets, such as enzymes or receptors, indicating possible pharmaceutical applications. Further research and testing are required to determine its specific properties and potential uses.

Uses

Used in Pharmaceutical Industry:
(2E)-2-(Hydroxyimino)-N-(3-methoxyphenyl)acetamide is used as a potential pharmaceutical agent for its ability to interact with biological targets, such as enzymes or receptors. Its specific applications and therapeutic effects would need to be established through additional research and clinical trials.
Note: Since the provided materials do not specify the exact uses or industries for (2E)-2-(Hydroxyimino)-N-(3-methoxyphenyl)acetamide, the above usage is a general statement based on the compound's potential pharmaceutical applications. Further information would be needed to provide more specific applications and industries.

InChI:InChI=1/C9H10N2O3/c1-14-8-4-2-3-7(5-8)11-9(12)6-10-13/h2-6,13H,1H3,(H,11,12)/b10-6-

Upstream product

• 536-90-3 m-Anisidine 
• 75-87-6 chloral 

Downstream Products

• 200010-61-3 [5-Hydroxy-8-methoxy-4-[(E)-methoxyimino]-1-(toluene-4-sulfonyl)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl]-propynoic acid ethyl ester 
• 200010-62-4 3-[5-Hydroxy-8-methoxy-4-[(E)-methoxyimino]-1-(toluene-4-sulfonyl)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl]-propionic acid ethyl ester 

Relevant articles and documents

MACROCYCLIC SERINE PROTEASE INHIBITORS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

Biological activities and quantitative structure-activity relationships of spiro[imidazolidine-4,4'(1'H)-quinazoline]-2,2',5(3'H)-triones as aldose reductase inhibitors

A series of spiro[imidazolidine-4,4'(1'H)-quinazoline]-2,2',5(3'H)-triones were prepared and tested for aldose reductase inhibitory activity. The 6'- halogenated derivatives were found to be highly potent in vitro inhibitors of male rabbit lens aldose reductase and in vivo inhibitors of polyol accumulation in the sciatic nerves of galactosemic rats. Of these, (4R)-6'- chloro-3'-methylspiro[imidazolidine-4,4'(1'H)-quinazoline]-2,2',5(3'H)-trione (67) showed the most potent in vitro and in vivo activities. An oral dose of 3 g/kg of compound 67 caused neither death nor behavioral abnormality in the preliminary acute toxicity study using mice and rats. Compound 67 was selected as a candidate for further evaluation. The quantitative structure- activity relationships in this series are also discussed.